These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21395349)

  • 1. Sample size and power for cost-effectiveness analysis (Part 2): the effect of maximum willingness to pay.
    Glick HA
    Pharmacoeconomics; 2011 Apr; 29(4):287-96. PubMed ID: 21395349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group.
    Everest L; Chen BE; Hay AE; Cheung MC; Chan KKW
    BMC Med Res Methodol; 2023 Aug; 23(1):179. PubMed ID: 37537545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power and sample size calculations for stochastic cost-effectiveness analysis.
    Briggs AH; Gray AM
    Med Decis Making; 1998; 18(2 Suppl):S81-92. PubMed ID: 9566469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Power and sample assessments for tests of hypotheses on cost-effectiveness ratios.
    Gardiner JC; Huebner M; Jetton J; Bradley CJ
    Health Econ; 2000 Apr; 9(3):227-34. PubMed ID: 10790701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
    Willan AR; O'Brien BJ
    Health Econ; 1999 May; 8(3):203-11. PubMed ID: 10348415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data.
    Willan AR
    Control Clin Trials; 2001 Jun; 22(3):228-37. PubMed ID: 11384787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using value of information methods to determine the optimal sample size for effectiveness trials of alcohol interventions for HIV-infected patients in East Africa.
    Li L; Uyei J; Nucifora KA; Kessler J; Stevens ER; Bryant K; Braithwaite RS
    BMC Health Serv Res; 2018 Jul; 18(1):590. PubMed ID: 30064428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new approach for sample size calculation in cost-effectiveness studies based on value of information.
    Bader C; Cossin S; Maillard A; Bénard A
    BMC Med Res Methodol; 2018 Oct; 18(1):113. PubMed ID: 30348087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis.
    Robinson R
    BMJ; 1993 Sep; 307(6907):793-5. PubMed ID: 8219957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
    Willan AR; O'Brien BJ
    Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size and power for cost-effectiveness analysis (part 1).
    Glick HA
    Pharmacoeconomics; 2011 Mar; 29(3):189-98. PubMed ID: 21309615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
    Shepherd J; Jones J; Frampton GK; Tanajewski L; Turner D; Price A
    Health Technol Assess; 2008 Jun; 12(28):iii-iv, ix-95. PubMed ID: 18547499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.
    Walter SD; Gafni A; Birch S
    Pharmacoeconomics; 2007; 25(6):455-66. PubMed ID: 17523751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
    Sarker SJ; Whitehead A; Khan I
    Comput Methods Programs Biomed; 2013 Jun; 110(3):471-89. PubMed ID: 23399102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The probability of cost-effectiveness.
    O'Hagan A; Stevens JW
    BMC Med Res Methodol; 2002; 2():5. PubMed ID: 11914138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.
    Hoch JS; Dewa CS
    Pharmacoeconomics; 2007; 25(10):807-16. PubMed ID: 17887803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness Analysis with Influence Diagrams.
    Arias M; Díez FJ
    Methods Inf Med; 2015; 54(4):353-8. PubMed ID: 25762363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size determination for cost-effectiveness trials.
    Willan AR
    Pharmacoeconomics; 2011 Nov; 29(11):933-49. PubMed ID: 21988292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size calculation in cost-effectiveness cluster randomized trials: optimal and maximin approaches.
    Manju MA; Candel MJ; Berger MP
    Stat Med; 2014 Jul; 33(15):2538-53. PubMed ID: 25019136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.